Neuromyelitis Optica Spectrum Disorder - A Closer Look at Recent Therapeutic Updates: Rapid Response From Amsterdam

Author(s)/Faculty: Benjamin M. Greenberg, MD, MHS, FANA, FAAN, CRND; Patricia K. Coyle, MD, FAAN, FANA; Prof. Dr. Friedemann Paul, MD
Release Date: 11/18/2022Expiration Date: 11/17/2023
Credit Type: CME / CNENumber of Credits: 1
Content Type: VideoProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. Early stages are frequently misdiagnosed. The application of newer diagnostic criteria may facilitate earlier and more accurate diagnosis by assisting neuro-ophthalmologists in the identification of individuals who might otherwise have been diagnosed with idiopathic transverse myelitis, idiopathic optic neuritis, or atypical multiple sclerosis. Until recently, treatment options have been limited, but the emergence of monoclonal antibody therapies has led to a shift in treatment paradigms. In this CME Rapid Response educational activity, an expert panel of clinicians evaluates disease burden, differential diagnosis, and emerging clinical evidence for newer treatment options. Faculty will review and discuss data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 annual conference in Amsterdam, the Netherlands.